Get the app
US › Healthcare

Kala Pharmaceuticals Inc (KALA)

US · Healthcare · Biotechnology

$0.56+8.24%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-1.6M
EPS
$-21.32

Key statistics

Market cap
$11.1M
Forward P/E
0.0
P/B
1.24
Book value
$0.47
EPS (TTM)
$-9.39
52-week high
$1,030.00
52-week low
$0.49
50-day MA
$0.83
200-day MA
$12.98
Beta
-2.29

Analyst view

Analysts rate Kala Pharmaceuticals Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $1.50.

Shareholding

Insiders
1.24%
Institutions
3.61%

Largest institutional holders

FundStake
Renaissance Technologies Corp0.04%
Geode Capital Management, LLC0.03%
Virtu Financial LLC0.02%
ADAR1 Capital Management LLC0.01%
UBS Group AG0.01%
Vanguard Capital Management, LLC0.01%
Jane Street Group LLC0.00%
JPMorgan Chase & Co0.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Kala Pharmaceuticals Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncNovo Nordisk A/SGilead Sciences IncAbbott Laboratories

Data updated 2026-09-18.